GLP-1 Baseline

GLP-1 receptor agonists (medications that mimic a natural gut hormone to reduce appetite and blood sugar) like semaglutide and tirzepatide change your body in ways that go far beyond the number on a scale. They reshape how you process sugar, how your liver handles fat, how much inflammation circulates in your blood, and how well you absorb nutrients. Without a clear snapshot of where all those systems stand before you start, you have no way to tell what the medication is actually doing for you, and no way to catch problems early.

That is what this panel provides: a single blood draw that maps the metabolic, nutritional, and safety markers most likely to shift once GLP-1 therapy begins. It turns your first follow-up lab from a guess into a comparison.

What This Panel Reveals

The tests in this panel cover six clinical domains: blood sugar control, lipid metabolism, inflammation, nutritional reserves, liver health, and electrolyte balance. Each one is tied to a specific way GLP-1 medications affect your body. No single domain tells the full story. Together, they give you a baseline you can track against for months or years.

Blood Sugar and Insulin Sensitivity

GLP-1 drugs work partly by stimulating your pancreas to release more insulin when blood sugar rises, and by slowing how fast food empties from your stomach. The metabolic markers in this panel capture how well your body currently handles sugar and how resistant your cells are to insulin's signal. In the SUSTAIN 6 trial, participants on semaglutide saw HbA1c (a measure of average blood sugar over about three months) drop by 1.0 to 1.4 percentage points over two years. In the SURPASS-2 trial, tirzepatide produced HbA1c reductions of up to 2.3 percentage points.

These improvements are meaningful, but they only matter if you know where you started. A fasting glucose of 126 mg/dL that drops to 100 mg/dL tells a different clinical story than one that starts at 95 mg/dL and barely moves. Pairing glucose and HbA1c with a fasting insulin level adds depth: you can see not just how high your sugar runs, but how hard your pancreas is working to keep it there.

Lipid Metabolism

Weight loss alone tends to improve cholesterol numbers, but GLP-1 medications appear to do more than what weight loss would predict. In the STEP 1 trial, semaglutide 2.4 mg reduced triglycerides (blood fats that spike after meals and drive cardiovascular risk) by 17.1% and LDL cholesterol by about 3.1% over 68 weeks, while raising HDL cholesterol by roughly 2.3%. The SELECT cardiovascular outcomes trial, which enrolled over 17,600 adults with established heart disease and obesity but without diabetes, found that semaglutide reduced major cardiovascular events (heart attack, stroke, or cardiovascular death) by 20%.

Your baseline lipid numbers establish whether the medication is pulling its weight on heart risk, or whether you need additional interventions like a statin (a cholesterol-lowering drug) or dietary changes on top of the GLP-1.

Systemic Inflammation

High-sensitivity C-reactive protein (hs-CRP) measures low-grade inflammation throughout the body. Chronic inflammation is a driver of heart disease, metabolic dysfunction, and insulin resistance. In the SELECT trial, semaglutide reduced hs-CRP by approximately 38% over the course of the study. This anti-inflammatory effect may partly explain the cardiovascular benefit that goes beyond what lipid and blood sugar changes would predict.

A baseline hs-CRP reading tells you how much background inflammation you carry into therapy, and whether the drug is helping to quiet it over time.

Nutritional Reserves

GLP-1 medications reduce appetite, often dramatically. When you eat substantially less food for months, you take in fewer vitamins and minerals. Three nutrients are especially vulnerable. Vitamin B12 (a nutrient your body needs for healthy nerves and red blood cells) can drop during prolonged caloric restriction, and reduced food intake on GLP-1 therapy may compound this risk over time. Folate (vitamin B9), which works alongside B12 in cell division and DNA repair, faces similar risks from reduced intake.

Vitamin D is already low in a large share of the population. Rapid weight loss can paradoxically release stored vitamin D from fat tissue initially, but prolonged caloric restriction and reduced dietary fat intake (which is needed for vitamin D absorption) can deplete levels over time. Knowing your baseline for all three nutrients means you can supplement early rather than discover a deficiency months in.

Liver Safety

The liver enzymes ALT (alanine aminotransferase) and AST (aspartate aminotransferase) serve as sentinels for liver stress. Many people starting GLP-1 therapy already have some degree of fatty liver disease, which itself causes elevated enzymes. In a clinical trial of semaglutide for non-alcoholic steatohepatitis (a form of liver inflammation caused by fat buildup), 59% of patients on the highest dose achieved resolution of their liver inflammation, compared to 17% on placebo. ALT levels dropped significantly in the treatment group.

A baseline reading distinguishes between pre-existing liver inflammation that the medication may actually improve and new liver stress that would warrant investigation.

Electrolyte and Hydration Balance

Nausea and vomiting are the most common side effects of GLP-1 medications, especially during the gradual dose increase. When you vomit repeatedly or reduce fluid intake because of nausea, you can lose electrolytes. Potassium and sodium shifts in particular can affect heart rhythm and muscle function. The FDA prescribing information for semaglutide specifically warns about dehydration risk from gastrointestinal side effects.

Baseline electrolyte values let you and your physician spot a dangerous shift quickly. Someone who starts with low-normal potassium and then develops persistent vomiting needs closer monitoring than someone who begins with levels solidly in range.

How to Read Your Results Together

Individual numbers matter, but the patterns across this panel tell a richer story. Here are the interpretation patterns most relevant before starting GLP-1 therapy.

When Results Can Be Misleading

HbA1c reflects average blood sugar over the prior two to three months. If you have been eating differently, fasting, or recently ill, your HbA1c and fasting glucose may not represent your usual metabolic state. Draw this panel during a period of normal eating for the most accurate baseline.

Acute illness, recent surgery, or intense physical stress can temporarily raise hs-CRP, ALT, and AST. If any of these results come back unexpectedly high, consider whether a recent illness could be the cause before attributing it to a chronic condition. A repeat draw two to four weeks later can clarify.

Dehydration at the time of the draw can concentrate your blood and artificially raise sodium, potassium, and calcium. Make sure you are reasonably well-hydrated (but still fasting if instructed) when you have this panel drawn.